Trial Profile
Treatment of Congenital Nephrogenic Diabetes Insipidus With a Guanylate Cyclase Stimulator, Riociguat or a Phosphodiesterase Type 5 Inhibitor, Sildenafil
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2019
Price :
$35
*
At a glance
- Drugs Riociguat (Primary) ; Sildenafil (Primary)
- Indications Diabetes insipidus
- Focus Therapeutic Use
- 06 Jun 2019 Status changed from recruiting to completed.
- 02 Jul 2018 New trial record